D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 85 Citations 39,050 1,008 World Ranking 9406 National Ranking 307

Overview

What is he best known for?

The fields of study Filippo de Braud is best known for:

  • Cancer
  • Chemotherapy
  • Gene

His work on Internal medicine as part of his general Toxicity study is frequently connected to Gastroenterology, thereby bridging the divide between different branches of science. His Internal medicine study frequently links to other fields, such as Toxicity. Filippo de Braud undertakes multidisciplinary studies into Gastroenterology and Oncology in his work. He integrates many fields, such as Oncology and Cancer research, in his works. By researching both Cancer research and Colorectal cancer, he produces research that crosses academic boundaries. Filippo de Braud merges Cancer with Regimen in his research. He merges many fields, such as Regimen and Chemotherapy, in his writings. Filippo de Braud undertakes multidisciplinary investigations into Chemotherapy and Neutropenia in his work. Many of his studies on Surgery apply to Randomized controlled trial as well.

His most cited work include:

  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer (3453 citations)
  • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study (659 citations)
  • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels (438 citations)

What are the main themes of his work throughout his whole career to date

Filippo de Braud has begun a study into Cancer, looking into Colorectal cancer and Breast cancer. Filippo de Braud performs integrative study on Colorectal cancer and Chemotherapy. He connects Chemotherapy with Cisplatin in his research. He combines topics linked to Phases of clinical research with his work on Internal medicine. Filippo de Braud integrates many fields, such as Oncology and Cancer research, in his works. In his works, he undertakes multidisciplinary study on Cancer research and Oncology. Many of his studies on Surgery apply to Regimen as well. His Regimen study frequently involves adjacent topics like Surgery. In his research, he performs multidisciplinary study on Gastroenterology and Internal medicine.

Filippo de Braud most often published in these fields:

  • Internal medicine (89.66%)
  • Oncology (63.22%)
  • Cancer (55.17%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

A. de Gramont;A. Figer;M. Seymour;M. Homerin.
Journal of Clinical Oncology (2000)

4864 Citations

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann.
Journal of Clinical Oncology (2009)

2063 Citations

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko.
The New England Journal of Medicine (2014)

1667 Citations

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko.
The Lancet (2015)

1276 Citations

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott.
Lancet Oncology (2016)

1097 Citations

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud.
Annals of Oncology (2011)

910 Citations

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

Daniel G. Haller;Josep Tabernero;Jean Maroun;Filippo De Braud.
Journal of Clinical Oncology (2011)

804 Citations

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel.
Cancer Discovery (2017)

604 Citations

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim.
Lancet Oncology (2016)

597 Citations

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

Yuchen Jiao;Timothy M Pawlik;Robert A Anders;Florin M Selaru.
Nature Genetics (2013)

590 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Filippo de Braud

Josep Tabernero

Josep Tabernero

Vall d´Hebron Institute of Oncology

Publications: 81

Dario Neri

Dario Neri

ETH Zurich

Publications: 72

Fortunato Ciardiello

Fortunato Ciardiello

University of Campania "Luigi Vanvitelli"

Publications: 62

Paolo A. Ascierto

Paolo A. Ascierto

National Institutes of Health

Publications: 61

Salvatore Siena

Salvatore Siena

University of Milan

Publications: 57

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 56

Thierry André

Thierry André

Université Paris Cité

Publications: 56

Eric Van Cutsem

Eric Van Cutsem

KU Leuven

Publications: 55

David Cunningham

David Cunningham

Royal Marsden NHS Foundation Trust

Publications: 54

Giovanni Paganelli

Giovanni Paganelli

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Publications: 53

Alexander Drilon

Alexander Drilon

Memorial Sloan Kettering Cancer Center

Publications: 48

Maurizio D'Incalci

Maurizio D'Incalci

Humanitas University

Publications: 48

Axel Grothey

Axel Grothey

University of Tennessee at Knoxville

Publications: 47

Heinz-Josef Lenz

Heinz-Josef Lenz

University of Southern California

Publications: 46

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 46

Andrés Cervantes

Andrés Cervantes

University of Valencia

Publications: 46

Something went wrong. Please try again later.